EP1089731A4 - Zusammensetzungen und verfahren zur behandlung von erhöhtem blutcholesterolspiegel - Google Patents

Zusammensetzungen und verfahren zur behandlung von erhöhtem blutcholesterolspiegel

Info

Publication number
EP1089731A4
EP1089731A4 EP99930451A EP99930451A EP1089731A4 EP 1089731 A4 EP1089731 A4 EP 1089731A4 EP 99930451 A EP99930451 A EP 99930451A EP 99930451 A EP99930451 A EP 99930451A EP 1089731 A4 EP1089731 A4 EP 1089731A4
Authority
EP
European Patent Office
Prior art keywords
compositions
methods
blood cholesterol
elevated blood
treating elevated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99930451A
Other languages
English (en)
French (fr)
Other versions
EP1089731A1 (de
Inventor
Edward M Scolnick
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9817167.1A external-priority patent/GB9817167D0/en
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of EP1089731A1 publication Critical patent/EP1089731A1/de
Publication of EP1089731A4 publication Critical patent/EP1089731A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
EP99930451A 1998-06-24 1999-06-21 Zusammensetzungen und verfahren zur behandlung von erhöhtem blutcholesterolspiegel Withdrawn EP1089731A4 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US9052798P 1998-06-24 1998-06-24
US90527P 1998-06-24
GBGB9817167.1A GB9817167D0 (en) 1998-08-06 1998-08-06 Compositions and methods for treating elevated blood cholesterol
GB9817167 1998-08-06
PCT/US1999/013887 WO1999066929A1 (en) 1998-06-24 1999-06-21 Compositions and methods for treating elevated blood cholesterol

Publications (2)

Publication Number Publication Date
EP1089731A1 EP1089731A1 (de) 2001-04-11
EP1089731A4 true EP1089731A4 (de) 2003-06-18

Family

ID=26314174

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99930451A Withdrawn EP1089731A4 (de) 1998-06-24 1999-06-21 Zusammensetzungen und verfahren zur behandlung von erhöhtem blutcholesterolspiegel

Country Status (5)

Country Link
EP (1) EP1089731A4 (de)
JP (1) JP2002518448A (de)
AU (1) AU754767B2 (de)
CA (1) CA2335366A1 (de)
WO (1) WO1999066929A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6350453B1 (en) 1999-05-24 2002-02-26 American River Nutrition, Inc. Tocotrienols and geranylgeraniol from Bixa orellana byproducts
AR040588A1 (es) 2002-07-26 2005-04-13 Schering Corp Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa
US20040202740A1 (en) * 2003-04-08 2004-10-14 Barrie Tan Annatto extract compositions, including geranyl geraniols and methods of use
EP2400840A4 (de) * 2009-02-24 2012-08-01 Madeira Therapeutics Flüssige statinformulierungen
WO2010126579A1 (en) * 2009-04-27 2010-11-04 Beth Israel Deaconess Medical Center Methods and compositions for the treatment and diagnosis of statin-induced myopathy
JP2015514686A (ja) 2012-02-29 2015-05-21 コヨーテ・ファーマシューティカルズ・インコーポレイテッドＣｏｙｏｔｅ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Ｇｇａ及びそのｇｇａ誘導体組成物並びにこれらを含む麻痺状態を含めた神経変性疾患を治療する方法
WO2014055440A1 (en) * 2012-10-01 2014-04-10 Coyote Pharmaceuticals, Inc. Preparation of gga and derivatives thereof and their co-crystallization with urea or thiourea
US9119808B1 (en) 2012-10-08 2015-09-01 Coyote Pharmaceuticals, Inc. Treating neurodegenerative diseases with GGA or a derivative thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2055100A (en) * 1979-07-27 1981-02-25 Sankyo Co Monacolin K derivatives
EP0671170A1 (de) * 1994-03-11 1995-09-13 Bristol-Myers Squibb Company Verwendung von Pravastatin zur Verlangsamung des Fortschreitens der Atherosklerose koronarer Arterien
US5622985A (en) * 1990-06-11 1997-04-22 Bristol-Myers Squibb Company Method for preventing a second heart attack employing an HMG CoA reductase inhibitor
WO1997019091A1 (en) * 1995-11-23 1997-05-29 Laboratori Baldacci S.P.A. Novel geranylgeranyl-derivatives, process for the preparation thereof and related pharmaceutical compositions
US5691375A (en) * 1994-01-18 1997-11-25 Bristol-Myers Squibb Company Method for preventing or reducing risk of onset of cardiovascular events employing an HMG CoA reductase inhibitor
JPH1087480A (ja) * 1996-09-13 1998-04-07 Eisai Co Ltd 抗動脈硬化治療剤

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4933165A (en) * 1989-01-18 1990-06-12 Merck & Co., Inc. Coenzyme Q10 with HMG-CoA reductase inhibitors
US5316765A (en) * 1989-09-07 1994-05-31 Karl Folkers Foundation For Biomedical And Clinical Research Use of coenzyme Q10 in combination with HMG-CoA reductase inhibitor therapies
CA2044162A1 (fr) * 1989-10-13 1991-04-14 Jacques Borg Derives des alcools gras a longue chaine, leurs applications, notamment en tant que molecules cytotrophes et cytoprotectrices, et compositions pharmaceutiques les contenant
US5639653A (en) * 1993-07-19 1997-06-17 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva Universtiy Method for proliferating Vγ2Vδ2 T cells
US5574025A (en) * 1994-10-26 1996-11-12 Merck & Co., Inc. Inhibitors of prenyl-protein transferases
US5763646A (en) * 1997-03-13 1998-06-09 Ranbaxy Laboratories, Ltd. Process for manufacturing simvastatin from lovastatin or mevinolinic acid

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2055100A (en) * 1979-07-27 1981-02-25 Sankyo Co Monacolin K derivatives
US5622985A (en) * 1990-06-11 1997-04-22 Bristol-Myers Squibb Company Method for preventing a second heart attack employing an HMG CoA reductase inhibitor
US5691375A (en) * 1994-01-18 1997-11-25 Bristol-Myers Squibb Company Method for preventing or reducing risk of onset of cardiovascular events employing an HMG CoA reductase inhibitor
EP0671170A1 (de) * 1994-03-11 1995-09-13 Bristol-Myers Squibb Company Verwendung von Pravastatin zur Verlangsamung des Fortschreitens der Atherosklerose koronarer Arterien
WO1997019091A1 (en) * 1995-11-23 1997-05-29 Laboratori Baldacci S.P.A. Novel geranylgeranyl-derivatives, process for the preparation thereof and related pharmaceutical compositions
JPH1087480A (ja) * 1996-09-13 1998-04-07 Eisai Co Ltd 抗動脈硬化治療剤

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
FLINT OLIVER P ET AL: "Inhibition of cholesterol synthesis by squalene synthase inhibitors does not induced myotoxicity in vitro.", TOXICOLOGY AND APPLIED PHARMACOLOGY, vol. 145, no. 1, 1997, pages 91 - 98, XP002237082, ISSN: 0041-008X *
PATENT ABSTRACTS OF JAPAN vol. 199, no. 809 31 July 1998 (1998-07-31) *
See also references of WO9966929A1 *

Also Published As

Publication number Publication date
AU4698999A (en) 2000-01-10
AU754767B2 (en) 2002-11-21
CA2335366A1 (en) 1999-12-29
EP1089731A1 (de) 2001-04-11
JP2002518448A (ja) 2002-06-25
WO1999066929A1 (en) 1999-12-29

Similar Documents

Publication Publication Date Title
IL112593A0 (en) Methods for inhibiting bone loss and lowering serum cholesterol
HK1048949A1 (en) Method and composition for the treatment of scars
EP1083835A4 (de) Methoden und geräte zur vaskularen chirurgie
HK1031174A1 (en) Compositions and methods for treating diabetes
AU6872498A (en) Method and composition for skin treatment
EP1217963A4 (de) Vorrichtungen und verfahren zur behandlung von gewebe
NZ514350A (en) Compositions and methods for effecting the levels of cholesterol
EP1022945A4 (de) Verfahren und formulierung zur behandlung von gefässerkrankungen
AU3387599A (en) Methods and compositions for tissue regeneration
IL142906A0 (en) Methods and compositions for treating or preventing peripheral neuropathies
IL115405A0 (en) Compositions and methods for treating mast-cell mediated conditions
IL140989A0 (en) Compositions and methods for treating osteoporosis and lowering cholesterol
ZA988016B (en) Compounds methods and pharmaceutical compositions for treating neural or cardiovascular tissue damage
EP1109548A4 (de) Zusammensetzungen und verfahren zur behandlung und vorbeugung von knochenkrankheiten unter verwendung von tocotrienole
ZA981600B (en) Methods and compositions for treating stickies
EP1089731A4 (de) Zusammensetzungen und verfahren zur behandlung von erhöhtem blutcholesterolspiegel
AU5594398A (en) Methods and compositions for preventing and treating bone loss
HUP0200829A2 (en) Agents and method for treating keratinous fibres
EP1089732A4 (de) Zusammenstellungen und methoden zur behandlung von erhöhtem blutcholesterolspiegel
AU5791698A (en) Methods and compositions for preventing and treating bone loss
GB9817167D0 (en) Compositions and methods for treating elevated blood cholesterol
GB9817174D0 (en) Compositions and methods for treating elevated blood cholesterol
AU5169200A (en) Methods and compositions for treating breakthrough pain
AU5097099A (en) Methods and compositions for cancer treatment
PL345261A1 (en) Method of treatment

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20010124

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU NL PT SE

AX Request for extension of the european patent

Free format text: AL PAYMENT 20010124;LT PAYMENT 20010124;LV PAYMENT 20010124;MK PAYMENT 20010124;RO PAYMENT 20010124;SI PAYMENT 20010124

A4 Supplementary search report drawn up and despatched

Effective date: 20030508

17Q First examination report despatched

Effective date: 20031106

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20040317